Colín LLJ

Language: Spanish
References: 4
Page: 26-30
PDF size: 57.44 Kb.

ABSTRACT

Hypertrophic cardiomyopathy is a relatively common genetic disorder with heterogeneity in mutations, forms of presentation, prognosis and treatment strategies. Hypertrophic cardiomyopathy is recognized as the most common cause of sudden cardiac death that occurs in young people, including athletes. The clinical diagnosis is complemented with the ecocardiographic study, in which an abnormal myocardial hypertrophy of the septum can be observed in the absence of a cardiac or systemic disease (arterial systemic hypertension, aortic stenosis). The annual sudden mortality rate is 1% and, in selected populations, it ranges between 3 and 6%. The therapeutic strategies depend on the different subsets of patients according to the morbidity and mortality, sudden cardiac death, obstructive symptoms, heart failure or atrial fibrillation and stroke. High risk patients for sudden death may effectively be treated with the automatic implantable cardioverter-defibrillator.

REFERENCES

1. Maron BJ: Hypertrophic Cardiomyopathy: A Systematic Review. JAMA 2002; 287: 10308-1320.

2. Elliot PM, Gimeno JR, Mahon NG, Polienicki JD, McKenna WJ: Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypetrophic cardiomyopathy. Lancet 2001; 357: 420.424.

3. Spirito P, Bellone P, Haris KM, Bernabo P, Bruzzi P, Maron BJ: Magnitud of the left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 2000; 342: 1778-1785.

4. Maron BJ, Shirani J, Poliac L, Mathenge R, Roberts W, Mueller F: Sudden Death in Young Competitive Athletes: Clinical, Demographic, and Pathological Profiles. JAMA 1996; 276: 199-204.